New Guidelines to Treat Advanced Prostate Cancer

New Guidelines to Treat Advanced Prostate Cancer
treatment guidelines for prostate cancerThe American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) have published a joint clinical practice guideline on treating men with metastatic castration-resistant prostate cancer (CRPC). The study entitled “Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline,” published in the Journal of Clinical Oncology, includes recommendations on systemic therapies indicated as an adjuvant of androgen deprivation, and addresses survival, quality of life benefits, side effects, and cost considerations for each. “We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years. There are a lot of nuances about treatment selection in terms of disease stage and what prior therapies the patient received. We hope this guideline will help doctors and patients make informed treatment decisions”, Ethan Basch, MD, co-chair of the ASCO/CCO Expert Panel that developed the guideline said in an
Subscribe or to access all post and page content.